Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft

PLoS One. 2013 Aug 15;8(8):e71362. doi: 10.1371/journal.pone.0071362. eCollection 2013.

Abstract

Background: A variety of surgical procedures are now available for tissue reconstruction after osteosarcoma excision, and an important prognostic factor is the evaluation of response to chemotherapy using histology. Although tumor-bearing autografts are useful tools for reconstruction, re-use of the primary tumor may make it difficult to assess the histological response to chemotherapy, since the entire tumor cannot be analyzed. Here, we analyzed the prognostic value of the histological response in the patients who received frozen tumor-bearing autografts for reconstruction.

Method: Retrospective analysis of the medical records of 51 patients with high-grade osteosarcoma of the extremities was performed. All patients received reconstruction using frozen tumor-bearing autografts. Tumor necrosis was evaluated in extraskeletal masses and cancellous bone.

Results: Five-year overall survival of patients with good and poor response to chemotherapy was 82.9% and 46.4%, respectively (P = 0.044), and 5-year event-free survival was 57.7% and 36.0%, respectively (P = 0.329). Multivariate analysis revealed that a poor histological response to chemotherapy was a significant prognostic factor for overall survival (P = 0.033).

Conclusion: Histological response is an important and reliable prognostic factor in patients undergoing reconstruction using frozen tumor-bearing autografts.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Autografts
  • Bone Neoplasms / mortality
  • Bone Neoplasms / pathology
  • Bone Neoplasms / surgery
  • Bone Neoplasms / therapy*
  • Bone Transplantation* / methods
  • Child, Preschool
  • Cryopreservation
  • Female
  • Histocytochemistry
  • Humans
  • Male
  • Middle Aged
  • Osteosarcoma / mortality
  • Osteosarcoma / pathology
  • Osteosarcoma / surgery
  • Osteosarcoma / therapy*
  • Prognosis
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents

Grants and funding

The authors have no funding or support to report.